Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

BMB. 2022; 7(2): 144-149


Clinicopathological Features and Prognostic Factors in Patients with Small Bowel Adenocarcinoma

Izzet Dogan, Didem Tastekin.




Abstract

Objective: Small bowel adenocarcinoma is a rare tumor, and data on prognosis is limited. We aimed to evaluate the clinicopathological features and prognostic factors in small bowel adenocarcinoma in this study.

Method: Twenty-two patients were evaluated. Clinicopathological features and treatment approaches were retrospectively recorded. Kaplan-Meier and Cox regression analyses were used to assess overall survival and prognostic factors.

Results: The origin sites of the tumor were the duodenum (50%), jejunum (31.8%), and ileum (18.2%), respectively. The number of de-novo metastatic patients was 11 (50%). The most common metastatic sites were the peritoneum (%45), liver (%41), and lymph nodes (18%). The median overall survival was 19.9 (7.3-32.5). One- and two-year survival ratios were 65.9% and 39%, respectively. The response ratio (complete or partial) of first-line chemotherapy in metastatic patients was determined at 46.2%. In multivariate analysis, surgery (p=0.024) and age at diagnosis (p=0.017) were statistically significant prognostic factors for OS. However, the site of the tumor (p=0.106), de-novo metastatic disease (p=0.323), and the number of metastatic sites (p=0.086) were not.

Conclusions: Patients with small bowel adenocarcinoma were diagnosed in advanced stages, and the prognosis of the disease was poor. We observed that removing the primary tumor improved survival, and being older than 60 years was a negative prognostic factor.

Key words: Small bowel adenocarcinoma, chemotherapy, prognosis






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.